{
    "ticker": "UNCY",
    "name": "Unicycive Therapeutics, Inc.",
    "description": "Unicycive Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for patients with chronic kidney disease (CKD). Founded in 2018, the company is focused on addressing unmet medical needs in the treatment of kidney-related conditions. Unicycive's lead product candidate,UNI-494, is a novel oral therapy designed to improve phosphate control in patients with CKD on dialysis, which is critical to managing the complications associated with the disease. The company is utilizing its proprietary platform to develop additional compounds that target various aspects of kidney health, aiming to advance the standard of care in nephrology. By leveraging insights from scientific research and clinical data, Unicycive aims to deliver transformative treatment options that enhance patient outcomes and quality of life. With a dedicated team of scientists and industry veterans, Unicycive Therapeutics is committed to innovation and excellence in renal therapeutics. The company\u2019s mission is to provide better treatment options for patients suffering from kidney diseases, thereby contributing to a healthier future.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.unicycive.com",
    "ceo": "Shawn K. McCarthy",
    "social_media": {
        "twitter": "https://twitter.com/Unicycive",
        "linkedin": "https://www.linkedin.com/company/unicycive-therapeutics/"
    },
    "investor_relations": "https://www.unicycive.com/investor-relations",
    "key_executives": [
        {
            "name": "Shawn K. McCarthy",
            "position": "CEO"
        },
        {
            "name": "David C. Hsu",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "UNI-494"
            ]
        }
    ],
    "seo": {
        "meta_title": "Unicycive Therapeutics, Inc. | Innovative Kidney Disease Therapies",
        "meta_description": "Explore Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic kidney disease. Learn about their lead product candidate and commitment to advancing renal health.",
        "keywords": [
            "Unicycive",
            "Chronic Kidney Disease",
            "Biopharmaceuticals",
            "Nephrology",
            "UNI-494"
        ]
    },
    "faq": [
        {
            "question": "What does Unicycive Therapeutics focus on?",
            "answer": "Unicycive Therapeutics focuses on developing innovative therapies for chronic kidney disease."
        },
        {
            "question": "What is UNI-494?",
            "answer": "UNI-494 is Unicycive's lead product candidate aimed at improving phosphate control in patients with chronic kidney disease."
        },
        {
            "question": "When was Unicycive founded?",
            "answer": "Unicycive was founded in 2018."
        },
        {
            "question": "Where is Unicycive headquartered?",
            "answer": "Unicycive is headquartered in San Diego, California, USA."
        }
    ],
    "competitors": [
        "ADMP",
        "KPTI",
        "CRIS"
    ],
    "related_stocks": [
        "GILD",
        "AMGN",
        "REGN",
        "VRTX"
    ]
}